Maze Therapeutics, Inc. (MAZE) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MAZE Hot Sheet
Join SI Premium – FREE
Maze Therapeutics, Inc. (NASDAQ: MAZE) reported Q2 EPS of ($0.77), $0.15 worse than the analyst estimate of ($0.62).
For earnings history and earnings-related data on Maze Therapeutics, Inc. (MAZE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aletheia Capital Reiterates Sell Rating on Apple (AAPL), PT $250, 'we expect both gross and operating margins to contract'
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- DA Davidson reiterates buy rating on Palantir with $250 price target
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
